Ning Yu Yuan, bedroom.

Zhang Ningxi was chasing the drama, and Si Mingyu was holding her mobile phone on her lap to reply to messages.

After leaving the medical research institute, Lin Shirui returned to her residence, and it was ridiculous once in a while, how could it be like this every night.

The second-generation group began to complain about Si Mingyu's "not participating in group activities" again. The key is where does he have so much spare time now, not to mention a lot of things in the group company for the time being, so many subordinate branches have to go to see it once a month, and he has to fly to Xiangjiang two or three times a month to deal with the affairs of East Asia Mingyu Hongming Industry.

And now that he has become famous, he has been invited to participate in more various activities, most of which are organized by business tycoons, and most of them are not in the magic capital, and it will take a day if he doesn't go, which is still on the premise that he has a private jet to go back and forth on the same day.

Besides, the six people in the group didn't want to think about what activities they had arranged. After seeing Si Mingyu's circle of friends in Sanya, they also wanted to rent a yacht by themselves, and then take a group of young ladies to reproduce the classic scene.

If you get closer, it's okay, running so far Si Mingyu doesn't think that this matter can be hidden from his daughter-in-law. So he politely refused, on the grounds that he had just come back and didn't want to go again.

"Daughter-in-law." Si Mingyu rubbed his head against Zhang Ningxi's legs.

"Don't move, itchy, there's something to say."

"My daughter-in-law is so beautiful."

"Keep boasting, don't stop." Zhang Ningxi touched his head.

"Ugh." Looks like that's not the case with the script.

Haw, his face was kissed by his daughter-in-law: "It's okay, let's talk about something." ”

"Uh-huh. I am ready to take a controlling stake in Peacock Feather Company. ”

"What's the new plan?" Zhang Ningxi knew that Si Mingyu never did useless work.

"In the past, the pharmaceutical research institute was relatively low-key, but now half of the success of new drug research and development has been concerned by all parties. Cosmetics and medicine are both chemical, and in fact, they can be combined in research and development, and the success of the pharmaceutical research institute can be used to endorse cosmetics for publicity. ”

"That's a good idea."

Cosmetics focus on the effect after use, regardless of the actual effect, it must be convinced that it is really effective.

After the drugs of the medical research institute are launched, they can promote popular cosmetics in the name of joint research and development. At that time, you can see that this R&D personnel have even overcome such a difficult disease, our company and this research institute have specially developed this product containing XX rare ingredients, using XX technology extraction, used to resist XX and enhance XX products, and the effect is very good after use.

This thing is the marketing concept, as long as someone believes that someone buys it, it is its own industry and there is no additional cost. Taking a step back, even if it is not successful, it is not a loss to increase its shareholding with the performance of Peacock Ling Cosmetics Company.

"Then it's decided, and then you will be the chairman, daughter-in-law."

Si Mingyu picked up the phone and called Wang Qinqin.

"Hello Mr. Si, what do you need?" Wang Qinqin's 24-hour full-time service Si Mingyu answered the phone as soon as possible.

"I am going to acquire 30% of the shares of Peacock Ling Cosmetics Company, and the money will be pledged with the shares of your bank for loans from China Merchants Bank, and how much will be used when the time comes, and the financial director of the group will dock with you."

"Okay."

Subsequently, Si Mingyu called Bian Guohai and Lu Jiamei, the manager of the asset management company, respectively, and asked the former to take over the loan and the latter to buy the shares. In addition to the outstanding shares, the remaining shares are in the hands of each shareholder, which needs to be negotiated one by one, and if the premium is high enough, someone is willing to transfer.

As for the amount of the loan, it depends on how much it costs in the end, and the loan can be disbursed after the loan agreement is signed, and the review is a process. There is nothing more reliable than taking a loan from China Merchants Bank as collateral for China Merchants Bank's stocks.

The so-called rare diseases are classified as rare diseases with a neonatal incidence rate of less than 1 in 10,000, a prevalence rate of less than 1 in 10,000, and a total number of patients less than 140,000.

So how expensive are drugs for rare diseases?

A drug developed by Novartis Pharmaceuticals in Switzerland for the treatment of spinal muscular atrophy was priced at $2.1 million that year.

It was also developed by Novartis Pharmaceuticals in Switzerland for periodic fever syndromes, including tumor necrosis factor receptor-related periodic syndromes, protein-related periodic syndromes, familial Mediterranean fever, etc., with a price tag of 370,000 US dollars a year. Yes, it costs so much money every year in order to carry out treatment.

Si Mingyu invested more than 13 billion yuan in R&D in the early stage, started the research and development of four drugs, and lost more than 2 billion yuan after three successes and one failure.

If the follow-up clinical trial is in China, it still needs to invest more than 10 billion yuan one after another, and if it is replaced by India, it can save more than half, and only more than 4 billion yuan is enough.

One of the three successful new drugs is a drug for the treatment of rare diseases, and even if it costs 1 million Chinese dollars a piece, it has to sell 700 pieces to recoup the cost. The other two are drugs for the treatment of common chronic diseases, which only need small profits but quick turnover, of course, this so-called small profit is compared with the previous drug.

There is no holiday in the Federation of 50 states except for the Spring Festival, so with the incentive of the bonus, the head of the research institute there has completed the procedures for conducting clinical trials in India in the shortest possible time, and everything is not a problem as long as there is money there.

Subsequently, a group of researchers and related personnel went to India happily with the items needed for the clinical trial and the travel allowance. This kind of thing has formed a related "industry" over there, so their work is not heavy, and it is basically equivalent to traveling.

As clinical trials began, patients around the world with such rare diseases immediately became intent. For them, this is a life-saving thing, once the phase I and phase II of the clinical trial are successfully completed, some people will take action without waiting for the start of phase III.

Because they can't afford to wait, it's not worth taking a little risk compared to their lives, and there are not a few people who think so. Yes, the percentage of patients with rare diseases is indeed small, but that is based on the world's population.

As for the two drugs for chronic treatment, there is no need to worry, just take your time.

In addition, Si Mingyu launched four new drug research and development projects after discussing with Li Zhenyuan. Although the R&D expenses are high, they do not require a one-time investment, and the annual R&D expenses of 400 million US dollars for the four drugs are equivalent to more than 2.5 billion Chinese dollars, and the income from the transportation and sale of natural gas by LNG ships alone is enough.

It is true that due to the increase in natural gas inventories in Europe, the price has dropped sharply, and the unloading capacity of the port has led to a large increase in the cost of LNG ships that cannot be unloaded for a long time, but because of the special channel, Si Mingyu can still achieve a monthly income of one billion Chinese dollars.

In addition, as long as you insist on waiting for a year for new drugs to be launched for the treatment of rare diseases, the medical research institute can be completely self-sufficient.